ArriVent BioPharma, Inc. (AVBP)
NASDAQ: AVBP · Real-Time Price · USD
22.91
+0.10 (0.44%)
Jun 27, 2025, 4:00 PM - Market closed
ArriVent BioPharma Employees
ArriVent BioPharma had 52 employees as of December 31, 2024. The number of employees increased by 12 or 30.00% compared to the previous year.
Employees
52
Change (1Y)
12
Growth (1Y)
30.00%
Revenue / Employee
n/a
Profits / Employee
-$2,451,115
Market Cap
783.81M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 52 | 12 | 30.00% |
| Dec 31, 2023 | 40 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
AVBP News
- 4 days ago - ArriVent Announces Positive Interim Firmonertinib Monotherapy Data From Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer and Plans to Advance into a Global Pivotal Study - GlobeNewsWire
- 7 days ago - ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC - GlobeNewsWire
- 6 weeks ago - ArriVent BioPharma Reports First Quarter 2025 Financial Results - GlobeNewsWire
- 2 months ago - ArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of Directors - GlobeNewsWire
- 4 months ago - ArriVent BioPharma Reports Full Year 2024 Financial Results - GlobeNewsWire
- 5 months ago - ArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal Cancers - GlobeNewsWire
- 10 months ago - ArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung Cancer - GlobeNewsWire
- 11 months ago - Aarvik Therapeutics Announces Option Exercise by Collaboration Partner ArriVent BioPharma - Business Wire